Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:ursodeoxycholic_acid
|
| gptkbp:approvedBy |
1990s
|
| gptkbp:ATCCode |
A05AA02
|
| gptkbp:contraindication |
acute inflammation of the gallbladder
calcified gallstones biliary tract obstruction |
| gptkbp:countryOfOperation |
gptkb:Australia
gptkb:Canada gptkb:Germany gptkb:Japan gptkb:United_Kingdom |
| gptkbp:eliminationHalfLife |
3.5-5.8 days
|
| gptkbp:form |
capsule
suspension |
| https://www.w3.org/2000/01/rdf-schema#label |
Ursofalk
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
Dr. Falk Pharma
|
| gptkbp:mechanismOfAction |
reduces cholesterol absorption
protects liver cells from bile acid toxicity |
| gptkbp:pregnancyCategory |
B (Australia)
B (US FDA) |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain |
| gptkbp:usedFor |
gptkb:primary_biliary_cholangitis
dissolution of cholesterol gallstones cholestatic liver diseases |
| gptkbp:bfsParent |
gptkb:ursodiol
|
| gptkbp:bfsLayer |
7
|